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Abstract
Objectives To carry out a further survey of archived appendix samples
to understand better the differences between existing estimates of the
prevalence of subclinical infection with prions after the bovine spongiform
encephalopathy epizootic and to see whether a broader birth cohort was
affected, and to understand better the implications for the management
of blood and blood products and for the handling of surgical instruments.
Design Irreversibly unlinked and anonymised large scale survey of
archived appendix samples.
Setting Archived appendix samples from the pathology departments of
41 UK hospitals participating in the earlier survey, and additional hospitals
in regions with lower levels of participation in that survey.
Sample 32 441 archived appendix samples fixed in formalin and
embedded in paraffin and tested for the presence of abnormal prion
protein (PrP).
ResultsOf the 32 441 appendix samples 16 were positive for abnormal
PrP, indicating an overall prevalence of 493 per million population (95%
confidence interval 282 to 801 per million). The prevalence in those born
in 1941-60 (733 per million, 269 to 1596 per million) did not differ
significantly from those born between 1961 and 1985 (412 per million,
198 to 758 per million) and was similar in both sexes and across the
three broad geographical areas sampled. Genetic testing of the positive
specimens for the genotype at PRNP codon 129 revealed a high
proportion that were valine homozygous compared with the frequency
in the normal population, and in stark contrast with confirmed clinical
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cases of vCJD, all of which were methionine homozygous at PRNP
codon 129.
Conclusions This study corroborates previous studies and suggests a
high prevalence of infection with abnormal PrP, indicating vCJD carrier
status in the population compared with the 177 vCJD cases to date.
These findings have important implications for the management of blood
and blood products and for the handling of surgical instruments.
Introduction
Variant Creutzfeldt-Jakob disease (vCJD) in the United
Kingdom and some other countries1 2was caused by an exposure
of the population to bovine spongiform encephalopathy (BSE)
prions. Large numbers of the UK population were exposed to
BSE prions in the late 1980s and early 1990s through
contaminated meat products in the food chain. vCJD differs
from other forms of Creutzfeldt-Jakob disease in that abnormal
prion protein (PrP) has been detected in tonsil biopsy tissues
before death and throughout the lymphoreticular system and
some other tissues after death.3 Accumulation of abnormal PrP
in follicular dendritic cells of lymphoreticular tissue is thought
to precede invasion of the central nervous system, and previous
observations4 5 have confirmed the presence of abnormal PrP
in archived surgical samples removed before the development
of clinical symptoms. Although there have been only 177 cases
of vCJD to date in the United Kingdom, it is likely that
subclinical carrier states of infection with vCJD prions exist,
particularly on crossing a species barrier after widespread low
dose exposure.6-9
In the United Kingdom, four prevalence surveys of abnormal
PrP have been reported to date5 10-12 (see supplementary table
1). In the face of continued uncertainty over the results of these
surveys, in 2008 the Spongiform Encephalopathy Advisory
Committee (SEAC (replaced in 2011 by the TSE Risk
Assessment Subgroup of the Advisory Committee onDangerous
Pathogens) advised a second immunohistochemistry survey of
archived appendix samples to increase understanding of the
differences between existing estimates of the prevalence of
subclinical abnormal prion infection and to see whether a
broader birth cohort was affected. This paper reports on the
findings of that second survey.
Methods
Sample collection, anonymisation, and data
handling
To screen at least 30 000 satisfactory appendix samples from
the 1941-60 and the 1961-85 birth cohorts, the Health Protection
Agency (since 1 April 2013 part of Public Health England)
collected 40 000 samples that had been removed at operations
between 2000 and 2012. The source appendix tissue, archived
in standard histology wax blocks (formalin fixed, paraffin
embedded) in 41 participating hospitals (see supplementary
table 4), was sent to Public Health England. Many of the
collaborating hospitals had participated in the earlier appendix
and tonsil survey5 by providing samples from appendectomies
before 2000 and agreed to provide additional samples. To
improve geographical representation of samples, we contacted
additional hospitals in regions with lower levels of participation
in the earlier survey, and collaboration was sought from the
heads of the histopathology departments.
At Public Health England, we selected a single block per case
and forwarded blocks in collections (“bins”) of 50 source
appendix samples to the two collaborating prion screening
laboratories, at University College London Institute of
Neurology and the Animal Health and Veterinary Laboratories
Agency, where sectioning, staining, and expert microscopic
examination was conducted. After quality assessment of the
sectioning and staining, each bin of samples was returned to the
laboratory at Public Health England. Before permission was
given to the screening laboratories to begin examination we
completed a robust, irreversible unlinking and anonymisation
procedure (fig 1⇓). At the Public Health England coordinating
laboratory, we created a survey database that included the survey
number, sex of the case, five year birth cohort, and broad
geographical area where the original appendicectomy hospital
was sited (fig 1, table 1⇓ and supplementary table 4). We
calculated exact binomial confidence intervals for the prevalence
estimates and compared prevalence between subgroups using
Fisher’s exact test with a 5% significance level.
Preparation of sections and
immunohistochemical detection of abnormal
PrP
From each paraffin block we cut a primary set of three sections.
We detected abnormal PrP using mouse monoclonal antiPrP
antibodies KG9 on one section and ICSM3510 12 13 on another
(see supplementary methods), visualised using a
peroxidase-diaminobenzidine detection kit (DABMapVentana
Medical System; Roche, Burgess Hill, UK) (fig 2 A-D, F-I⇓).
To investigate suspect cases and confirm positive ones, we
repeated the staining on additional, subsequent sections and
with antiPrP monoclonal antibodies (3F4 and 12F10, see
supplementary methods) (fig 2 P-S). Both laboratories used
identical equipment (Ventana Discovery XT; Roche, Burgess
Hill, UK), reagents, and protocols. We also stained half of the
samples with haematoxylin and eosin to assess the proportion
affected by inflammation.We assessed each section set to ensure
the presence of five or more follicles and whether the tissue
contained appendix biopsy tissue or other tissue that may have
been collected in error. In addition to the appendix samples, we
occasionally identified non-appendix tissue containing lymphoid
follicles and we included this tissue when it met the criteria.
From any samples with possible follicular immunoreactivity,
we prepared 12 additional 4 µm sections and three 10 µm
paraffin rolls (fig 1). To determine how the presence of florid
granulocytic (purulent) inflammation affected the detection of
follicular dendritic cells in secondary follicles, appendixes that
met the inclusion criteria (≥5 follicles present), in particular
where follicles were partially overrun by granulocytes, we
carried out CD21 immunostaining—an established marker for
follicular dendritic cells14—on five samples each with minimal,
moderate, or severe inflammation (see supplementary fig 1).
Expert examination
Once irreversibly anonymised, expert examination at UCL
Institute of Neurology (SB) or the Animal Health and Veterinary
Laboratories Agency (MMS/YS) categorised samples as either
positive, suspect, non-specific, or negative. A positive sample
showed immunolabelling of a characteristic follicular dendritic
cell network within a germinative centre of a follicle and at least
one follicle had to contain a small network of immunopositive
follicular dendritic cells. The positive follicular dendritic cells
had to be present either in consecutive sections in the same
follicle, or in a different follicle on a deeper section. A suspect
sample had either weak immunoreactivity in a follicle that did
not correspond to the typical pattern of PrP positive follicular
dendritic cell, or weak, equivocal reactive staining that was not
reproducible on consecutive sections (fig 3 K, M⇓). Specimens
classified as non-specific showed antibody binding in the follicle
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5675 doi: 10.1136/bmj.f5675 (Published 15 October 2013) Page 2 of 12
RESEARCH
centres—for example, in degraded tissue that did not show
typical follicular dendritic cell morphology (fig 3 J, L, N).
Negative samples showed no immunoreactivity; specific
labelling of non follicular dendritic cell structures within
follicles, such as macrophages; non-specific (background)
labelling inside the follicles; or labelling of structures outside
the follicles (see supplementary fig 1). We then referred all
section sets of interest (positive and suspect immunolabelling)
to other experts (JWI and DH) for two independent repeat
examinations, including staining of spare sections at the National
CJD Research and Surveillance Unit (fig 3 C). Finally, at three
meetings the expert histopathologists reviewed each written
report and slide set to arrive at a consensus opinion of the
findings.
Determination of PRNP codon 129 genotype
We determined the codon 129 genotype of positive samples and
a selection of others using allele discrimination with minor
groove binding probes. For primary assay, we used a reverse
transcription polymerase chain reaction, which was confirmed
with a polymerase chain reaction based restriction endonuclease
analysis (see supplementary methods).
Results
Material examined and exclusion of unsuitable
specimens
A total of 40 022 paraffin wax blocks were processed in 801
bins; 20 041 at UCL Institute of Neurology and 19 981 at the
Animal Health and Veterinary Laboratories Agency. Overall,
80 044 immunolabelled slides underwent initial assessment. In
addition, 5720 control sections and approximately 4000 repeat
sections (5%) were assessed. From the 40 022 appendix
specimens collected, 19% (7500 samples) were rejected because
either no viable follicles were present, the follicles were overrun
or destroyed by inflammation, fewer than five follicles were
present, or the tissue was atrophied. The rejection rate varied
between the sample bins, from zero in 50 (six bins) to 29 in 50
(one bin). Altogether, 1995 repeat sections were made usually
because ofmachine failures (54%), incomplete dewaxing (14%),
or peroxidase-diaminobenzidine debris (12%) (see
supplementary table 3).
Detection of abnormal PrP in appendix
samples and distribution of PRNP codon 129
genotypes
The survey included appendixes from operations conducted
between 2000 and 2012. Of the 32 441 appendixes included,
16 met the criteria for being positive; selected sections for nine
of these 16 appendixes are shown (fig 3 A-I). The number of
positive follicles, the size of the affected follicular dendritic cell
area, and the strength of the immunolabelling, varied between
these 16 samples (for example, fig 2 U-Y; table 1), and positive
labelling was always confined to the follicular dendritic cells
in germinative centres of the secondary follicles. Another two
appendix samples met the criteria for being suspect (fig 3 K,
M; table 1). Nine samples showed non-specific antibody binding
in the follicle centre, owing to necrotic degradation of the
appendix as a result of appendicitis (for example, fig 3 J, L, N).
The remaining samples were classified as negative.
Of the 16 positive appendix samples, eight were methionine
homozygous at PRNP codon 129, four methionine-valine
heterozygous, and four valine homozygous (table 1). One of
the two suspect appendixes wasmethionine-valine heterozygous
and the other was valine homozygous. Transverse and
longitudinal sections were available in the 16 positive
appendixes (table 1). Positive follicles were not uniformly
distributed but showed an irregular distribution with strong
labelling in several adjacent follicles on one cross section (fig
2 U-Y), and fewer or no positive follicles on a different
transverse or longitudinal level. Between 2% and 20% of
follicles present, in all available sections, were positive in five
of the 16 positive samples (the codon 129 genotype was
methionine homozygous in three, and methionine-valine
heterozygous and valine homozygous in the others); between
25% and 60% in seven samples (three methionine homozygous,
two methionine-valine heterozygous, and two valine
homozygous) and 75% to 89% in four samples (twomethionine
homozygous, one methionine-valine heterozygous, and one
valine homozygous). Thus the morphology, staining intensity,
distribution, and proportion of positive follicles (fig 3) were
independent of the codon 129 genotype (table 1).
Difference between antibodies used in this
study
Strong labelling was usually produced by antiPrP antibody
ICSM35 (fig 2 A, B), whereas antiPrP antibody KG9 generally
showed weaker immunoreactivity in the same follicles on
immediately adjacent sections (fig 2 F, G), in contrast with
sporadic Creutzfeldt-Jakob disease brain sections, where both
antibodies showed identical signals (fig 2 C, D, H, I).
Application of different retrieval methods for the positive
appendix samples, such as longer microwaving or autoclaving,
or formic acid pretreatment, did not increase KG9
immunoreactivity. Having observed the difference between
ICSM35 and KG9 on the initial positive appendixes, we further
applied well established diagnostic antibodies 3F4 and 12F1015 16
to sections adjacent to any positively labelled sections, and again
immunolabelling generally was weaker or undetectable (for
example, fig 2 K, L, P, Q). All four antibodies yielded a strong
signal on brain sections (fig 2 C, H, M, R and D, I, N, S) and
formic acid treated tonsil biopsy samples from vCJD cases (fig
2 E, J, O, T).
Follicular dendritic cells degradation in
inflamed appendixes
Robust CD21 immunolabelling of follicular dendritic cell was
seen in all follicles in appendixes with no or minimal
granulocyte infiltration (see supplementary fig 1 A-C), whereas
fewer CD21 positive follicular dendritic cells were seen in
moderately inflamed appendixes (see supplementary fig 1 D-F)
and none in severely inflamed appendixes, where follicles were
overrun by inflammatory cells (see supplementary fig 1 G-I).
This indicates that the exclusion of inflamed appendixes from
the survey samples was justified, as no PrP immunolabelled
follicular dendritic cell would have been detectable.
Prevalence of abnormal PrP by birth cohort,
sex, and geographical area
The observed prevalence of abnormal PrP was 493 per million
population overall (table 2⇓). The prevalence of 733 per million
(95% confidence interval 269 to 1596 per million) seen in those
born in 1941-60 was not significantly different from the 412
per million (198 to 758 per million) seen in those born between
1961 and 1985. When these two birth cohorts were subdivided
into nine birth cohorts (1941-45, 1946-50, etc), there was at
least one positive appendix in each cohort apart from the
1961-65 cohort (table 2). Although 10 of the positive appendixes
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had been collected frommen and six fromwomen, the difference
was not statistically significant. When the samples collected
from 41 hospitals throughout England (see supplementary table
4) were grouped into three broad geographical areas (north east
and north west; south east coast, south west, and London; and
East and West Midlands), there were no apparent geographical
differences in abnormal prion prevalence. Because all the survey
appendixes were collected from operations conducted between
2000 and 2012, and the previous operative history of the 177
vCJD cases in the United Kingdom is known, it can be
concluded that none of the positive appendixes came from
known vCJD cases.
Discussion
In 32 441 formalin fixed paraffin embedded appendix samples,
we found 16 specimens positive for abnormal prion protein
(PrP), indicating a prevalence of 493 per million population
overall, and it was similar in both sexes and across the three
broad geographical areas sampled.
Although the overall prevalence estimate, 493 per million (95%
confidence interval 282 to 801 per million), was double the
point estimate measured in the earlier survey of appendixes (237
per million, 49 to 692 per million),5 the estimated prevalence
range largely overlapped that from the first survey but was
narrower with a higher central estimate (1:2000 v 1:4000). The
current survey also shows the presence of PrP across a wider
birth cohort than found previously.
Genotypes of positive appendix samples
A striking finding of the first appendix survey was the presence
of the valine homozygous genotype at PRNP codon 12917 in
two of the three positive samples. The present, larger study
gives amore representative picture of the frequency of genotypes
and the variation of immunolabelling in these positive
appendixes: 50% of the 16 positive samples were methionine
homozygous at PRNP codon 129, 25% methionine-valine
heterozygous, and 25% valine homozygous, in contrast with
the normal distribution in the population of 43%, 45%, and 13%,
respectively (see supplementary fig 2). When we combined the
findings from both appendix studies, a higher number of valine
homozygous cases were observed than would be expected (6
of 18) in the genotyped appendixes compared with the overall
UK population genotype frequency18 (P=0.02, Fisher’s exact
test). This increase of valine homozygous genotypes in positive
appendix specimens differed from the 177 patients with vCJD,
all of whom to date have beenmethionine homozygotes (P<10−5,
Fisher’s exact test, see supplementary fig 2).1 3 19 20
Technical aspects of the antibodies
On a technical aspect, our study revealed a performance
difference between the antibodies used, whereby ICSM35 had
a higher signal to noise ratio than either KG9, 12F10, or 3F4.
This is in contrast with previous studies where 3F4 and KG9
were used. The previous appendix survey21 used 3F4 and KG9
but not ICSM35. All antibodies detected weak cortical PrP
labelling in autopsymaterial (fig 2 D, I, N, S) and were validated
with formic acid treated tonsil biopsies (fig 2 E, J, O, T). The
appendix biopsy samples were material from surgery, usually
rapidly and short term fixed in formalin and not treated with
formic acid. It is possible that ICSM35 was more sensitive at
detecting abnormal PrP in such biopsy samples and that the
other three antibodies benefit from formic acid treatment after
formalin fixation, as suggested in figure 1 E, J, O, T.
Importantly, all four antibodies detected the same cell type in
immunolabelled follicles of positive appendix samples.
Several studies have validated immunohistochemistry in
combination with appropriate retrieval techniques as an adequate
tool to detect abnormal PrP and underpin the validity and
reliability of previous studies and the present study to detect
abnormal PrP in archival material,22 23 despite the unavailability
of antibodies specific for abnormal PrP and suitable for formalin
fixed, paraffin embedded material. Importantly, these studies
also concluded that lymphoreticular accumulation of abnormal
PrP is a specific feature of vCJD in prion diseases in humans.
Sensitivity of the tests
For several reasons, immunohistochemically detected positivity
in appendixes may underestimate the prevalence of abnormal
PrP. Firstly, it is assumed that tissue in an appendix block is
adequately represented by the two adjacent sections that were
screened. Although under-sampling would be a problem only
in those appendixes that contained positive follicular dendritic
cells in one or a few follicles, such biological variation could
cause our method to have reduced sensitivity and lead to an
underestimate of the prevalence of abnormal PrP. Animal
pathogenesis studies suggest that at early stages of the incubation
period the number of positive follicles is low and increases with
incubation time.24 Secondly, the proportion of positive
appendixes at post-mortem examination in vCJD cases has been
found to vary from 19 of 20 (95%)21 to one of four (25%)25 (see
supplementary table 1). Thirdly, we confirmed by using CD21
immunostaining for follicular dendritic cell that inflammation
destroys these cells, hence reducing the number of potentially
positive samples (fig 1). In our series, however, only 12% of
appendixes were rejected owing to inflammation (see
supplementary table 2) and the absence of labelling of abnormal
PrP in any of the acutely inflamed appendixes that were
examined makes it unlikely that inflammation triggers PrP
deposition. Fourthly, as with the first appendix survey, a
limitation of the second survey for estimating the prevalence
of asymptomatic infection and predicting future numbers of
vCJD cases is that it is not known at what stage during the
incubation period abnormal PrP can be detected in lymphoid
tissue.
Discrepancy between prevalence estimates
and vCJD incidence
To date the discrepancy is growing between the prevalence of
vCJD prions observed in the exposed population and the
relatively small number of patients who have developed vCJD,
whatever the true sensitivity and specificity of prion specific
immunohistochemistry in appendixes. The number of patients
with clinically manifest vCJD (177 cases at June 2013) is well
below the number suggested by the prevalence of abnormal
prion, even for those who are only methionine homozygous at
PRNP codon 129 (an estimated 6000 cases). Nevertheless, these
data are in keeping with recent animal experiments, which
suggest that the human transmission barrier for bovine
spongiform encephalopathy (BSE) may be high for clinical
disease but substantially lower for peripheral lymphoreticular
infection.26 Although clinical disease (infection of the central
nervous system with vCJD prions) may greatly favour the
methionine homozygous genotype, peripheral lymphoreticular
infection may be much less selective, or even favour the valine
homozygous genotype (see supplementary fig 2). Therefore,
the prevalence data raise several important issues. Firstly, it is
not known whether hosts who are methionine-valine
heterozygous or valine homozygous and carry immunopositive
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lymphoreticular tissues are protected from developing vCJD or
if they will eventually develop clinical prion disease, and if so
how prolonged the incubation period would be. Secondly, it is
unclear the extent to which the risk of developing vCJD in
someone who is methionine homozygous decreases with age at
exposure and whether this decrease is so great that a perpetual
asymptomatic carrier state is the result. Thirdly, it is not known
whether carriers pose a risk of transmitting the disease through
surgical procedures27 or through blood and other tissue donation.
Finally, it is not known whether host carriers who are
methionine-valine heterozygous and valine homozygous and
develop clinical prion disease will present with clinical signs
of vCJDwith the PrP glycotype corresponding to type 42 28 (also
designated type 2b29). The PrP glycotype is a biochemical
signature, determined by the glycosylation of specific sites of
the PrPmolecule which distinguishes sporadic and variant CJD.2
It is possible that the transmission of vCJD through
contaminated blood into people who are methionine-valine
heterozygous29 30 also results in a type 4 (2b) glycotype
characteristic for vCJD (like those with methionine
homozygosity) or may it instead present with a different, novel
phenotype and glycotype, as suggested by some experimental
transmission studies.31-33 Some answers may come through case
surveillance, especially when combined with routine testing of
the PRNP codon 129 genotype, and by testing the PrP glycotype
of central nervous system samples in all autopsies of patients
with prion disease, regardless of their clinical presentation.
Data from blood transmission studies in sheep suggest that blood
infectivity is present early in the incubation period, whatever
the primary route of infection.34 If a precautionary approach is
adhered to, and it is assumed that the presence in humans of
abnormal PrP in lymphoreticular tissue is synonymous with
blood infectivity, then the observed prevalence of abnormal
prion suggests that more instances of vCJD transmission by
blood transfusion should have been recognised in the United
Kingdom by now.35 Should transmission by way of blood
transfusion prove efficient in humans, subject to certain
assumptions mathematical modelling suggests that only a small
number of future vCJD cases may be expected to arise in both
the methionine-valine heterozygous and valine homozygous
genotypes through primary transmission. Instead, a larger
number of future cases may occur as a result of secondary
iatrogenic transmission in all genotypes, and should this
secondary epidemic arise, it would do so over decades.27
Before concluding that the clinical course of BSE related
abnormal PrP in humans must differ from that in sheep, it would
be prudent to measure the prevalence of abnormal PrP in human
blood. As soon as a satisfactory human blood screening test
becomes available in a scalable format, such an unlinked
anonymous survey should be undertaken.Meanwhile, although
the discrepancy between prevalence of abnormal PrP in
appendixes and observed cases of vCJD as a result of blood
transmission suggests that the risks of transmission of vCJD by
blood transfusion are low, it is unclear how many blood
recipients may have subclinical disease and if their life
expectancy is shorter than the incubation time. Therefore it is
essential to continue research into tests to detect abnormal PrP
in blood.
Conclusions
The second appendix survey has provided the most robust
measure of abnormal prion prevalence to date, and has shown
a wider birth cohort and all genotypes to be affected.
Interpretation of these findings will be aided by a further survey,
already begun, of appendix specimens surgically removed before
the BSE epizootic, in the mid to late 1970s, to inform about
prevalence in the absence of dietary exposure.
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Tables
Table 1| Summary of appendix samples with positive, suspect, or non-specific immunolabelling for abnormal prion protein (PrP), by sex,
geographical area, birth cohort, codon 129 genotype, and analysis of PrP positive follicles,* and a detailed breakdown of ICSM35
immunolabelling, and number of follicles with weak (+), intermediate (++), and strong (+++) positivity†
Analysis of PrP positive and negative follicles
Codon
129
Demographic and area information
Case No,
survey No
ICSM35§ positivity in folliclesKG9‡
Birth
cohort
Geographical
area, EnglandSex Fig No
No
positive/all
follicles
(%)SectionNegative+++++++ to +++
Positive
samples:
3A10/28 (35)TS156—42MM1946-50NorthM1, 13119
TS24———0
TS39———0
3G2/10 (20)TS41——1VV1956-60South and
London
F2, 14784
TS24—1—1
3D4/7 (57)TS101210MV1971-75South and
London
M3, 15048
TS23———0
LS0———0
3B4/5 (80)TS013—2MM1976-80South and
London
M4, 16937
LS1———0
3H5/11 (45)TS102—30VV1966-70NorthF5, 25173
TS23———0
LS3———0
3E2/11 (18)TS1611—0MV1971-75NorthF6, 25612
TS23———0
2A, B,
F, G, K,
L, P, Q
25/28 (89)TS10—3—0MV1956-60Midlands and
east
M7, 28441
TS211110
LS24692
3I4/11 (36)TS154——2VV1966-70NorthF8, 31327
TS20———0
LS2———0
3F,
2U-Y
12/15 (80)TS11—2—0VV1956-60Midlands and
east
F9, 32182
TS2042—0
TS3213—0
1/41 (2)TS1211——0MM1981-85Midlands and
east
M10, 34039
TS25———0
LS14———0
1/4 (25)TS10———0MV1966-70South and
London
M11, 36521
TS23——11
TS30———0
3C6/50 (12)TS12——10MM1981-85South and
London
F12, 38647
TS22——20
LS4021—1
6/16 (38)TS18———0MM1976-80South and
London
M13, 39047
TS21—1—0
TS315——0
1/9 (11)TS10———0MM1976-80South and
London
M14, 39121
TS251——1
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5675 doi: 10.1136/bmj.f5675 (Published 15 October 2013) Page 7 of 12
RESEARCH
Table 1 (continued)
Analysis of PrP positive and negative follicles
Codon
129
Demographic and area information
Case No,
survey No
ICSM35§ positivity in folliclesKG9‡
Birth
cohort
Geographical
area, EnglandSex Fig No
No
positive/all
follicles
(%)SectionNegative+++++++ to +++
LS3———0
3/4 (75)TS11——30MM1951-55South and
London
M15, 42181
TS20———0
TS30———0
3/5 (60)TS10—211MM1941-45South and
London
M16, 42660
TS21——10
LS102—12
LS221111
Suspect
samples:
3M1/10 (10)TS14———0VV1956–1960Midlands and
east
F1, 18992
TS25——10
TS30———0
3K1/16 (6)TS0———0MV1961–1965South and
London
U2, 20050
LS16——10
Non-specific
staining:
3J———————MM1951–1955South and
London
M1, 15368
3L———————MM1961–1965South and
London
U2, 19878
—————————1981–1985South and
London
U3, 20174
3N———————VV1961–1965South and
London
F4, 28791
————————MM1971–1975NorthF6, 25655
—————————1956–1960NorthF5, 31000
—————————1976–1980Midlands and
east
M6, 31616
—————————1961–1965Midlands and
east
M7, 31753
—————————1981–1985Midlands and
east
F8, 34591
—————————1951–1955South and
London
F9, 42713
MM=methionine homozygous; VV=valine homozygous; MV=methionine-valine heterozygous; U=unknown.
Most of the specimens showed an uneven distribution of positive follicles—that is, only in one of several sections within the specimen (for example, 13119, 15048,
16937, 25173, 25612, 31372).A few showed a homogenous distribution of positive follicles across all parts of the specimen (for example, 14784, 28441 or 32182).
This distribution was independent of the intensity of staining of individual follicles.
*Number of follicles positive with KG9.
†Specimens contained transverse sections (TS) and longitudinal sections (LS) of tissue with variable numbers of positive and total follicles.
‡Mouse monoclonal antiPrP antibody KG9.
§Mouse monoclonal antiPrP antibody ICSM35.
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Table 2| Prevalence of abnormal prion protein in appendix samples from operations conducted in England between 2000 and 2012 by area,
sex of patient, and five year birth cohort
Total (including unknown
sex)
East Midlands and West MidlandsSouth east coast, south west, and LondonNorth east and north west
Birth cohort MaleFemaleMaleFemaleMaleFemale
1/14200/1920/1831/2860/2960/1630/1651941–45
1/19180/2620/2720/3480/4011/2090/1961946–50
1/21240/2880/2851/3720/4740/2630/2481951–55
3/27191/3891/3570/5021/5900/3160/3211956–60
0/34380/4930/4330/6090/6620/4200/4511961–65
3/40900/5740/5121/7740/7300/5542/5021966–70
2/44080/6200/5201/8080/8850/5301/5241971–75
3/51840/6400/6333/10490/10350/6340/5941976–80
2/71401/8680/7070/14171/15510/8640/8241981–85
16/32 4412/43261/39027/61652/66241/39533/3825Total
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Figures
Fig 1 Process from block collection to returning blocks to participating hospitals (see supplementary file for full details)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5675 doi: 10.1136/bmj.f5675 (Published 15 October 2013) Page 10 of 12
RESEARCH
Fig 2 Immunolabelling of positive appendix samples and positive control sections stained during same machine run. First
and second column: abnormal prion protein (PrP) in positive appendix sample (A28441). A, B: robust immunolabelling with
antibody ICSM35 in several follicles (A). Higher magnification (B) shows characteristic labelling of follicular dendritic cells
in one follicle. C, D: immunolabelling of section that served as external positive control in same machine cycle, containing
section of cerebellum (C) or weak synaptic or perineuronal net labelling in the frontal cortex (D). F, G: antibody KG9 shows
weaker but unequivocal immunolabelling of immediately adjacent section, whereas other antibodies (3F4, K, L) and 12F10,
P, Q) do not show any signal. All cerebellar sections show robust immunolabelling (C, H, M, R) and there is less intense
labelling of a cortical ribbon (D, I, N, S), characteristic of sporadic Creutzfeldt-Jakob disease with type 3 glycopattern.
Antibody 12F10 shows slightly weaker detection of cortical PrP (N). Formic acid treated tonsil biopsy shows intense
immunolabelling pattern with ICSM35 and KG9. U-Y: distribution of weak, intermediate, and strong immunolabelling of
positive appendix (A32182). Red squares in low power overview (Q) correspond to panel R-U. Appendix shows positive
labelling in 12 of 15 follicles. U; section corresponding to TS1 (see table 1) is on top, TS2 is located bottom left, and TS3
bottom right. Scale bar corresponds to 400 µm (first, third, and fourth columns; A, C, D, F, H, I, K, M, N, P, R, S), 100 µm
(second column, B, G, L, Q), 6 mm (U), and 200 µm (vCJD tonsil column E, J, O, T and V-Y)
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Fig 3 Examples of appendix samples diagnosed as positive, suspect, and non-specific for abnormal prion protein (PrP).
A-C: examples of positive samples with methionine homozygous genotype at PRNP codon 129. Intrafollicular distribution
and intensity of PrP show some variation, and all follicles show crisp, robust staining of follicular dendritic cells. Inset in C
shows area with follicular dendritic cell at high magnification. D-F: three samples with variable positive labelling, illustrating
variability in size and intensity of staining. Inset in F shows high magnification of follicular dendritic cell in centre. G-I: positive
follicular dendritic cell in cases with valine homozygous genotype at PRNP codon 129, showing similar variability as previous
cases. K, M: suspect cases, showing weak labelling of structures that may correspond to follicular dendritic cell, but not
confirmed in subsequent immunostains. J, L, N: non-specific cases, with antibody binding to structures in follicle centre that
do not correspond to viable follicular dendritic cell. J and N are necrotic follicles where follicular dendritic cell structure has
disappeared, and L shows antibody binding in an area of poor morphological preservation. Scale bar 200 µm (50 µm in
insets)
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